Management and outcome of HER2-positive early breast cancer treated with or without trastuzumab in the adjuvant trastuzumab era.
Palmieri C, Shah D, Krell J, Gojis O, Hogben K, Riddle P, Ahmad R, Tat T, Fox K, Porter A, Mahmoud S, Kirschke S, Shousha S, Gudi M, Coombes RC, Leonard R, Cleator S.
Palmieri C, et al. Among authors: krell j.
Clin Breast Cancer. 2011 Apr;11(2):93-102. doi: 10.1016/j.clbc.2011.03.001. Epub 2011 Apr 11.
Clin Breast Cancer. 2011.
PMID: 21569995